CMSC

John Dirk Nieland, PhD, associate professor in the Department of Health Science and Technology at Aalborg University in Denmark, discusses his research team's connection between MS and lipid metabolism, the importance of condition-inflicted models, and the encompassing nature of treating MS.

Clyde Markowitz, MD, discusses how ocrelizumab, the most recent FDA-approved multiple sclerosis (MS) treatment, doesn't need to have "blockbuster" results to progress the state of MS treatment.

"We shouldn't reject these hypotheses, we should seek more data on them.

He and a Danish team believe they've found the cause of multiple sclerosis.

Brenda Banwell, MD, FAAP, FRCPC, Children's Hospital of Philadelphia's Neurology Division chief, talks about the cruciality of early diagnosing in pediatric multiple sclerosis patients, and how their best outcome is just being able to live a normal, everyday life.

Brenda Banwell, MD, FAAP, FRCPC, chief of Childrens Hospital of Philadelphia's Division of Neurology, speaks on new discoveries of pediatric MS at the annual 2017 Consortium of Multiple Sclerosis Centers (CMSC) in New Orleans.

The multi-dosage longterm studies of Cladribine Tablets were shared at CMSC.

The study was a continuation of a 2-year alemtuzumab study versus interferon.

The director of experimental therapeutics at the Mellen MS Center at the Cleveland Clinic shared what's shaping the soon-to-be-released update on the most recent 2010 diagnosing criteria at the 2017 Consortium of Multiple Sclerosis Centers.

The Mount Sinai Hospital neurology professor shares his thoughts on MS care.

The study presented at CMSC 2017 compared the treatments to an interferon.

Stephen Krieger, MD, an associate professor at Mount Sinai Hospital, discusses the impact that recently-approved drug ocrelizumab has on the state of multiple sclerosis care, as well as his patient-centered app that depicts the MS condition in a more accurate manner, at the 2017 Consortium of Multiple Sclerosis Centers in New Orleans.

Physicians debated the case of a 65-year-old woman with SPMS.

Physicians debated whether they would prescribe the new MS drug to a patient.

Allen Bowling, MD, PhD, physician associate of the Colorado Neurological Institute, discussed widely-researched benefits of cannabis on MS effects, its shortcomings, and the broad outcomes of alternative treatment.

Clyde Markowitz, MD, director of the MS Center at the University of Pennsylvania, discusses how the patterns of male-to-female ratio in MS diagnoses may be linked to hormones, and whether testosterone could be key in bettering treatment.

An overview of the newest treatment options for the disease.

At CMSC 2017, Aaron Boster, MD, neuroimmunologist for OhioHealth Neurological Clinicians, discussed why he believes there's never been a better time of opportunity for multiple sclerosis patients, and what must be improved in MS diagnosis practice.

The genetic, environmental, and immune factors behind the disease.

Physicians received an overview of the scope and severity of the disease.

It was not that long ago when doctors would sometimes not discuss the diagnosis of multiple sclerosis with their patients. Now not only is it a condition they can diagnose but treatment is also progressing by leaps and bounds.

Newly approved and longstanding treatment options are definitely an important part of the overall care picture but there is more work for a doctor to do beyond filling out a prescription pad.

As the treatment of relapsing remitting multiple sclerosis continues to add new treatment methods patients with progressive forms of the condition are still waiting for their first approved medication to manage their symptoms.

Acknowledging that uncertainty is a key factor in the care and treatment of multiple sclerosis is part of a solution to a problem, finding the best way to deal with that uncertainty is another issue that must be confronted by patients and doctors alike.

From the time a patient is diagnosed with multiple sclerosis there are often more questions than answers for extended periods of time. What that means for their care and management of symptoms is the subject of a recent study.

With a lot of the attention in multiple sclerosis care turning to finding treatments for progressive forms of the disease those who suffer relapses are in some ways being left in the shadows of treatment discoveries and care.

A recently concluded survey looked at issues most affecting patients with multiple sclerosis that they may not have been willing or able to discuss with health care providers but could help others with the condition in the future.

New medications are constantly being developed and approved for the treatment of multiple sclerosis. How those treatments are used and what the future holds for the disease remains to be seen.

There are known differences between men and women when it comes to multiple sclerosis and the likelihood of developing the disease. There are also differences in how best to treat patients given their gender.

In a chronic condition where depression is a known symptom treating the mental condition of a patient can be just as important as the physical aspects especially when suicide prevention is part of the overall care.